--- title: "Lakewood-Amedex Biotherapeutics (LABT) news: reverse split" url: "https://aibio.space/companies/lakewood-amedex-biotherapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LABT reverse split, going concern and IPO news: Lakewood-Amedex holders approve share increase and reverse split authority." --- LABT Lakewood-Amedex Biotherapeutics Inc. NASDAQ · United States # Lakewood-Amedex Biotherapeutics (LABT) news LABT reverse split, going concern and IPO news Listings · 2026-09-29 ## [Lakewood-Amedex holders approve share increase and reverse split authority](https://aibio.space/news/lakewood-amedex-holders-approve-share-increase-reverse-split-authority/) Stockholders voted on September 22, 2026 to raise authorized common shares from 12,500,000 to 100,000,000. The board may now carry out reverse splits at a cumulative ratio up to one-for-twenty. ## Latest Lakewood-Amedex Biotherapeutics news 1. 2026-08-10 Listings [Lakewood-Amedex Biotherapeutics sets vote on share increase to 100,000,000 and reverse split](https://aibio.space/news/lakewood-amedex-biotherapeutics-sets-vote-share-increase-100-000-000/) Holders will vote on September 22, 2026 on raising authorized common stock from 12,500,000 shares and on a reverse split of up to 1-for-20. 2. 2026-06-17 Listings [Lakewood-Amedex Biotherapeutics sets 1-for-10 reverse split, trading June 22, 2026](https://aibio.space/news/lakewood-amedex-biotherapeutics-sets-1-10-reverse-split-trading-june/) Outstanding shares will fall from about 17,506,577 to about 1,750,789. The stock stays on the Nasdaq Capital Market as LABT. 3. 2026-04-23 Financings [Lakewood-Amedex files prospectus for Nasdaq direct listing of 4,689,177 shares](https://aibio.space/news/lakewood-amedex-files-prospectus-nasdaq-direct-listing-4-689-177/) The company will receive no proceeds from the resale. It also has agreements to sell 937,500 shares of Series C Preferred Stock for gross proceeds of $7,500,000, and its audited 2025 statements carry a going concern warning. ## Lakewood-Amedex Biotherapeutics at a glance - **Ticker**: LABT - **Listing**: NASDAQ - **Country**: United States ### Related companies - [BioAge Labs](https://aibio.space/companies/bioage-labs/) NASDAQ: BIOA - [Seres Therapeutics](https://aibio.space/companies/seres-therapeutics/) NASDAQ: MCRB - [Zenas BioPharma](https://aibio.space/companies/zenas-biopharma/) NASDAQ: ZBIO - [Palvella Therapeutics](https://aibio.space/companies/palvella-therapeutics/) NASDAQ: PVLA - [Alto Neuroscience](https://aibio.space/companies/alto-neuroscience/) NYSE: ANRO - [Dianthus Therapeutics](https://aibio.space/companies/dianthus-therapeutics/) NASDAQ: DNTH - [TuHURA Biosciences](https://aibio.space/companies/tuhura-biosciences/) NASDAQ: HURA - [Jade Biosciences](https://aibio.space/companies/jade-biosciences/) NASDAQ: JBIO ### Also on NASDAQ - [Roivant Sciences](https://aibio.space/companies/roivant-sciences/) ROIV - [ClearPoint Neuro](https://aibio.space/companies/clearpoint-neuro/) CLPT - [Caribou Biosciences](https://aibio.space/companies/caribou-biosciences/) CRBU - [GRI Bio](https://aibio.space/companies/gri-bio/) GRI - [NuCana](https://aibio.space/companies/nucana/) NCNA - [ACCURAY INC](https://aibio.space/companies/accuray/) ARAY ## Questions about Lakewood-Amedex Biotherapeutics Did Lakewood-Amedex Biotherapeutics do a reverse stock split? Our latest story on this, dated Sep 29, 2026: "Lakewood-Amedex holders approve share increase and reverse split authority". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lakewood-amedex-holders-approve-share-increase-reverse-split-authority/). Has Lakewood-Amedex Biotherapeutics issued a going-concern warning? Our latest story on this, dated Apr 23, 2026: "Lakewood-Amedex files prospectus for Nasdaq direct listing of 4,689,177 shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lakewood-amedex-files-prospectus-nasdaq-direct-listing-4-689-177/). When did Lakewood-Amedex Biotherapeutics go public? Our latest story on this, dated Apr 23, 2026: "Lakewood-Amedex files prospectus for Nasdaq direct listing of 4,689,177 shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lakewood-amedex-files-prospectus-nasdaq-direct-listing-4-689-177/). What is the ticker symbol of Lakewood-Amedex Biotherapeutics? Lakewood-Amedex Biotherapeutics Inc. trades under the ticker LABT on NASDAQ. Where is Lakewood-Amedex Biotherapeutics listed? Lakewood-Amedex Biotherapeutics Inc. is listed on NASDAQ. What is the SEC CIK of Lakewood-Amedex Biotherapeutics? The SEC Central Index Key (CIK) for Lakewood-Amedex Biotherapeutics Inc. is 2079272. Its filings are on SEC EDGAR. How many shares does Lakewood-Amedex Biotherapeutics have outstanding? 2,369,688 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Lakewood-Amedex Biotherapeutics listed under? Our directory records Lakewood-Amedex Biotherapeutics Inc. under United States. What does Lakewood-Amedex Biotherapeutics do? Our directory classifies Lakewood-Amedex Biotherapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Lakewood-Amedex Biotherapeutics? The ISIN recorded for Lakewood-Amedex Biotherapeutics Inc. is US51255A2015. Does aibio.space cover Lakewood-Amedex Biotherapeutics? aibio.space lists Lakewood-Amedex Biotherapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Lakewood-Amedex Biotherapeutics incorporated? SEC records list its state or country of incorporation as NV. What is the latest Lakewood-Amedex Biotherapeutics (LABT) stock news? Our latest story on Lakewood-Amedex Biotherapeutics, dated Sep 29, 2026: "Lakewood-Amedex holders approve share increase and reverse split authority". Stockholders voted on September 22, 2026 to raise authorized common shares from 12,500,000 to 100,000,000. The board may now carry out reverse splits at a cumulative ratio up to one-for-twenty. [Source](https://aibio.space/news/lakewood-amedex-holders-approve-share-increase-reverse-split-authority/). What is Lakewood-Amedex Biotherapeutics's latest stock offering or financing news? Our latest financing story, dated Apr 23, 2026: "Lakewood-Amedex files prospectus for Nasdaq direct listing of 4,689,177 shares". The company will receive no proceeds from the resale. It also has agreements to sell 937,500 shares of Series C Preferred Stock for gross proceeds of $7,500,000, and its audited 2025 statements carry a going concern warning. [Source](https://aibio.space/news/lakewood-amedex-files-prospectus-nasdaq-direct-listing-4-689-177/). Who were the underwriters or placement agents on Lakewood-Amedex Biotherapeutics's offering? From our story: RBW Capital Partners LLC is the company's financial advisor for the listing, under a February 10, 2025 agreement covering financial advisory, financial placement agency and investment banking services. [Source](https://aibio.space/news/lakewood-amedex-files-prospectus-nasdaq-direct-listing-4-689-177/). ## Investor discussion: Lakewood-Amedex Biotherapeutics Members talk about Lakewood-Amedex Biotherapeutics (LABT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Lakewood-Amedex Biotherapeutics, newest first. Each line links the filing it comes from. 1. 2026-09-29 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/2079272/000121390026104177/ea0306660-8k_lakewood.htm) 2. 2026-09-18 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/2079272/000121390026101512/ea0305803-s1_lakewood.htm) 3. 2026-08-10 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/2079272/000121390026087336/ea0301384-01.htm) 4. 2026-07-30 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/2079272/000121390026083353/ea0299275-pre14a_lakewood.htm) 5. 2026-06-17 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/ea0294845-8k_lakewood.htm) 6. 2026-04-23 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/2079272/000121390026047113/ea0248668-15.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LABT on TradingView](https://www.tradingview.com/symbols/NASDAQ-LABT/). ## SEC filings and registration - **SEC name**: Lakewood-Amedex Biotherapeutics Inc. - **CIK**: 2079272 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: LABT (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 8031 COOPER CREEK BLVD., UNIVERSITY PARK, FL, 34201 - **Phone**: 9412252515 - **Shares outstanding**: 2,369,688 as of 2026-08-03 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/2079272/000121390026104177/ea0306660-8k_lakewood.htm) filed 2026-09-29 - [S-1](https://www.sec.gov/Archives/edgar/data/2079272/000121390026101512/ea0305803-s1_lakewood.htm) filed 2026-09-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/2079272/000121390026089380/ea0299462-10q_lakewood.htm) filed 2026-08-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/2079272/000121390026087336/ea0301384-01.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/2079272/000121390026078328/ea0297963-8k_lakewood.htm) filed 2026-07-15 - [8-K](https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/ea0294845-8k_lakewood.htm) filed 2026-06-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/2079272/000121390026060640/ea0291215-10q_lakewood.htm) filed 2026-05-22 - [S-1](https://www.sec.gov/Archives/edgar/data/2079272/000121390026050936/ea0286535-s1_lakewood.htm) filed 2026-05-01 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002079272), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Lakewood-Amedex Biotherapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LABT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Lakewood-Amedex Biotherapeutics Inc. - **Ticker**: LABT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US51255A2015 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LABT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lakewood-amedex-biotherapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lakewood-Amedex Biotherapeutics (LABT) news: reverse split", 2026-10-31, https://aibio.space/companies/lakewood-amedex-biotherapeutics/